Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of BI 1467335 in Moderate Renal Impairment
NCT03302091Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1467335 in Plasma Over the Time Interval From 0 to 24 Hours After Administration of the First Dose (AUC0-24), Maximum Measured Concentration of BI 1467335 in Plasma After Administration of the First Dose (Cmax) at Day 1 and 2 more. Started Oct 2017; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03302091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03302091.